1 month Royal Bank of Canada Reaffirms Outperform Rating for Sarepta Therapeutics (NASDAQ:SRPT)MarketBeat
Royal Bank of Canada reaffirmed an “outperform” rating and issued a $182.00 price objective on shares of Sarepta Therapeutics in a research note on Monday.
Canada · Nasdaq 100 · Royal Bank of Canada · Science
X